Samsung Biologics said it signed a contract manufacturing organization (CMO) agreement worth 420 billion won ($296 million) with GlaxoSmithKline (GSK).

Samsung Biologics has disclosed that it signed a CMO deal with GSK worth 420 billion won.
Samsung Biologics has disclosed that it signed a CMO deal with GSK worth 420 billion won.

The contract period is from Oct. 11, 2022 to Dec. 31, 2030.

However, Samsung Biologics refused to disclose which drug the deal covers, as requested by GSK.

This is the second largest CMO contract that Samsung Biologics signed this year and accounts for 26.8 percent of its 2021 sales.

The deal comes after Korea’s largest CDMO company has been in close cooperation with the British pharma. Samsung Biologics had previously signed two agreements with GSK in February and March.

In 2022, the total amount of Samsung Biologics’ CMO deals reached 1.7 trillion won as of Thursday.

 

Copyright © KBR Unauthorized reproduction, redistribution prohibited